A novel neoadjuvant therapy combining PD-1 blockade and chemoradiotherapy shows promising results in treating advanced rectal ...
In this phase 2 study, researchers explored whether fecal microbiota transplant could overcome resistance to immune checkpoint inhibition.
Pharmaceutical Technology on MSN
Eisai signs $388m deal for Japanese rights to Henlius’ anti-PD-1 mAb
Eisai will now take ownership of the Japanese rights to differentiated anti-PD-1 therapy, Hetronifly.
Moderna’s (MRNA) mRNA-based cancer therapy, intismeran autogene (mRNA-4157), with Merck’s (MRK) anti-PD-1 therapy, Keytruda, reduced the risk of tumor recurrence or death by 49% over five years in a ...
Complete response rate was 37%, and post-hoc end point of objective response rate was 89%. HealthDay News — Patients with advanced desmoplastic melanoma have high response to single-agent ...
SAN FRANCISCO and SUZHOU, China, March 30, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...
RFA and anti-PD-1 combination therapy suppresses abscopal HCC tumors and prevents recurrence in mice
Hepatocellular carcinoma (HCC), the most prevalent form of primary liver cancer, remains a leading cause of cancer-related mortality worldwide. Although radiofrequency ablation (RFA) is the first-line ...
Camrelizumab plus albumin-bound paclitaxel and S-1 as first-line treatment of HER-2 negative unresectable locally advanced or advanced gastric and gastroesophageal junction adenocarcinoma: A phase II ...
A fourth of patients with advanced, anti-PD-1-resistant melanoma responded to the viral mimetic BO-112 plus pembrolizumab. Responses were durable with over half of responding patients alive at 24 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results